Clinical trials have established the average benefit of cardiac resynchronization therapy (CRT), but estimating benefit for individual patients remains difficult because of the heterogeneity in treatment response. Accordingly, we created a multivariable model to predict changes in quality of life (QoL) with and without CRT.
F
or patients with advanced systolic heart failure and a widened QRS, guidelines recommend several therapies, including cardiac resynchronization therapy (CRT), to improve survival and quality of life (QoL). 1, 2 It is inherently difficult, however, to apply guidelines to individual patients whose benefits from treatment may differ substantially from the average benefit described in clinical trials. This issue is of particular concern for CRT, which requires a relatively complex, expensive, invasive procedure compared with a pharmacological therapy that can easily be given for a trial period and easily withdrawn if it causes problems. Also, the response to CRT is heterogeneous, some patients improve, whereas others worsen. In general, patients are 8% to 10% more likely to experience a favorable improvement in diseasespecific QoL with versus without CRT. [3] [4] [5] [6] Previous efforts to create risk models to personalize the estimated benefits of CRT have focused on survival. 7 Importantly, such models do not inform patients and their providers of the likely benefits of CRT on the patient's QoL. 3 Given the importance of QoL to patients, 8 formally modeling the heterogeneity of treatment benefit for QoL outcomes can assist physicians in patient selection, enable more accurate discussions of the risks and benefits of treatment, and support shared medical decision making. [9] [10] [11] To address the need for a tool to individualize treatment based on anticipated QoL benefits for individual patients, we used patient-level data from 5 randomized trials of CRT to develop a multivariable risk prediction model of QoL benefit after CRT.
METHODS

Data Source
Patient-level data were pooled from 5 randomized controlled trials of CRT therapy and included 4317 patients. Details of the CARE-HF (cardiac resynchronization-heart failure), MIRACLE (Multicenter InSync Randomized Clinical Evaluation), MIRACLE-ICD (Multicenter InSync ICD Randomized Clinical Evaluation), REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction), and RAFT studies (Resynchronization-Defibrillation for Ambulatory Heart Failure Trial) have been described previously. 3, 4, [12] [13] [14] Each trial was approved by an institutional review board, and informed consent was obtained. The pooled data set was completely deidentified and considered nonhuman subjects research. Although there were differences among the trials, all included adult patients with a diagnosis of chronic heart failure, left ventricular dysfunction, and a wide QRS complex. All trials had at least 6 months of follow-up and collected disease-specific health status data at baseline and follow-up. Given the paucity of data on patients with New York Heart Association (NYHA) class I, we restricted the analyses to those with NYHA II to IV.
Health Status Measures
Disease-specific health status was assessed in the trials using the Minnesota Living with Heart Failure Questionnaire (MLHFQ) and Kansas City Cardiomyopathy Questionnaire (KCCQ). 15, 16 The MLHFQ was collected in all 5 trials, whereas the KCCQs were collected only in REVERSE. The MLHFQ contains 21 questions and has a range in overall scores of 0 to 105 points, with lower scores indicating better QoL. The KCCQ is a 12-or 23-item instrument that ranges in overall scores from 0 to 100 points, where higher scores indicate better health status. 17 Both instruments have been shown to be reliable, responsive, and valid measures of patients' heart failure symptoms, functional status, and disease-specific QoL. However, the data for interpreting what constitutes clinically important changes in overall score has been more clearly defined for the KCCQ, 18 where a 5-, 10-, and 20-point change in the KCCQ overall summary score corresponds to a small, moderate, and large clinical change in patients' health status. 8, 18, 19 
Selecting the Time for Modeling Health Status Benefits
Given the variability in the timing of QoL collection among the trials, we needed to define a suitable time for modeling follow-up health status. The most QoL data were available at 3 months (Table I in the Data Supplement) . However, to ensure that 3 months was a sufficient length of time for the QoL benefits of CRT to be attained, we evaluated the change in QoL from baseline to 3, 6, and 12 months. For the MLHFQ, across all patients, there was a mean improvement
WHAT IS NEW?
• The results of clinical trials average the benefit of treatment across a population, but the expected benefits for individual patients can vary substantially.
• While cardiac resynchronization therapy has a small average benefit on patients' health status (their symptoms, function, and quality of life), some patients benefit a lot and others do not.
• Using 5 randomized clinical trials, we built a model to predict the health status benefits of cardiac resynchronization therapy for individual patients using only 3 variables: age, QRS width, and baseline health status.
WHAT ARE THE CLINICAL IMPLICATIONS?
• By using this new model, clinicians can calculate whether patients are likely to have a large, moderate, or small health status benefit from cardiac resynchronization therapy or whether they are unlikely to feel worse 3 or 12 months after treatment.
• The results of this model can not only inform clinicians but can also be shared with patients as a foundation for shared medical decision making.
• Future studies to define the benefit of this tool in patient engagement, clinical outcomes, and as a component of disease management should be tested.
of −12.4 from baseline to 3 months. At 6 months, the mean MLHFQ change from baseline was −12.7, with no significant difference between the changes from baseline at month 3 and month 6, (P=0.10); Figure I in the Data Supplement). We, therefore, selected the 3-month health status assessment to model the heterogeneity of treatment benefit from CRT. To evaluate the models' performance on longer-term outcomes, a sensitivity analysis evaluating calibration and discrimination was conducted on patients with 12-month QoL data available.
Defining Clinically Important Changes in QoL
To improve the clinical interpretability of the models and support their use in patient selection and shared decision making, we sought to model clinically important categories of change, rather than modeling the MLHFQ as a continuous score. Given that there are much clearer thresholds to interpret the magnitude of change that is clinically important with the KCCQ, we modeled the improvement in the MLHFQ associated with small, moderate, or large improvements in KCCQ scores. 18, 19 To perform this analysis, we used data from REVERSE, which simultaneously collected both the MLHFQ and KCCQ. Changes in KCCQ from baseline to 3 months suggested that a small clinical improvement in the MLHFQ questionnaire was −6.67 points; a moderate improvement was −10.41 points; and a large clinical improvement was −17.90 points (Data Supplement).
Statistical Analyses
As particular patients may find different levels of change in QoL clinically relevant, we used a cumulative logit model to estimate the heterogeneity of treatment benefit with CRT. This cumulative logit model can be thought of as an extension of the logistic regression model that applies to dichotomous dependent variables, allowing for >2 (ordered) response categories. It uses cumulative probability up to a possible threshold, thereby making the whole range of ordinal categories binary at that particular threshold. In this study, we used 4 cutoff points for MLHFQ change from baseline at 3 months (>−2.92 reflecting deterioration, <−6.67 for a small QoL improvement, <−10.41 for a moderate QoL improvement, and <−17.9 for a large QoL improvement). The cumulative logit model thus enables the estimation of the probabilities that a patient will be worse (>−2.92 points), unchanged (−2.92 to −6.67 points), slightly (−6.67 to −10.4 points), moderately (−10.4 to −17.9 points), or substantially better (<−17.9 points) at 3 months.
Candidate variables were selected a priori on the basis of published literature and clinical experience and included age, sex, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, β-blockers, left ventricular ejection fraction, left ventricular end diastolic dimension, diabetes mellitus, QRS duration, left bundle branch block, MLHFQ at baseline, CRT, atrial rhythm, and ischemic cardiomyopathy. Spironolactone use and NYHA class at baseline were both highly collinear with baseline QoL and thus omitted as candidate variables. Interactions between CRT and other variables were examined and retained if statistically significant. We used stepwise variable selection to select the final variables for the model. The assumption of linearity was assessed for each continuous variable with the use of restricted cubic splines. The proportional odds assumptions were tested for all variables included in the final model and assumptions held for all variables except baseline QoL, requiring separate intercepts for each category of 3-month QoL change. To take into clustering of patients by study, study was included a random effect.
Discrimination (C statistic) was calculated for each binary cumulative outcome at each threshold of clinical change. In sensitivity analysis, calibration plots were created by comparing observed versus predicted probability by decile of no change, small improvement, moderate improvement, and large improvements in QoL. Statistical analyses were conducted with SAS, version 9.3 (SAS Institute, Cary, NC), and R version 2.7.2.
RESULTS
Study Population
Of the 4317 patients from the 5 trials, 98 patients were excluded because they died before the 3-month QoL assessment (censored at end of randomization period).
Patients not surviving to 3 months were older, with a worse QoL, and generally sicker at baseline (Table II in the Data Supplement). We also excluded patients without baseline (n=117) or 3-month QoL data (n=388) and excluded the patients with NYHA class 1 (n=100), leaving 3614 patients for this analysis, of whom 1890 were assigned to CRT. Patients excluded for missing QoL data had better baseline QoL and were more likely to be on a β-blocker, however, other baseline characteristics were similar to the analytic cohort (Table III in the Data Supplement). Mean age of the cohort was 65±10 years, 78% were men, 30% had diabetes mellitus, and 58% had an ischemic cardiomyopathy. Mean left ventricular ejection fraction was 24±6%, mean QRS duration was 162±24 ms, and 76% had a left bundle branch block. Mean MLHFQ at baseline was 42.4±23.4. Baseline characteristics between CRT and controls were generally well balanced with the exception of more patients in the CRT cohort being NYHA II (52.2% versus 48.3%; P=0.017) and on β-blockers (80.3% versus 76.7%; P=0.008; Table IV in the Data Supplement).
Change in QoL and CRT Effect
Among the 3614 patients, regardless of assigned treatment, 33.3% had deterioration in QoL, 9.2% had no change, 9.2% had a small improvement, 13.5% had a moderate improvement, and the remaining 34.9% had a large improvement. The baseline characteristics of patients, stratified by change in QoL, are presented in Table. From baseline to 3 months, the MLHFQ score improved, on average, by −14.0±20.6 with CRT versus −10.3±20.8 with optimal medical therapy for a mean difference of 3.7 points (P<0.001), which is less than the estimated minimally important difference of −6.67 points. However, there was considerable heterogeneity in response (Figure 1 ). For patients in NYHA III or IV at baseline (n=1795), the mean difference between CRT and optimal medical therapy was −6.3 (P<0.0001) points, but for those in NYHA II (n=1819), it was only −1.5 points (P=0.10). In a responder analysis, which categorizes patients' changes in QoL into worse (>−2.92 points), unchanged (−2.92 to 6.67 points), slightly (−6.67 to −10.4 points), moderately (−10.4 to −17.9 points), or substantially better (<−17.9 points) patients undergoing CRT were less likely to have a decrement in their QoL (28.2% versus 38.9%; P<0.001) and more likely to have a large QoL improvement (38.7% versus 30.6%; P<0.001; Table V in the Data Supplement). These differences were more marked in patients who were in NYHA III or IV at baseline compared with those in NYHA II, respectively (Figure 2A and 2B) .
Predictors of QoL Improvement
The partial proportional odds model identified baseline QoL, age, and an interaction of CRT with QRS duration as significant predictors of improvement in QoL at 3 months. (Figure 3 ). Patients with wider QRS duration had the greatest benefit from CRT. Worse baseline QoL and older age were associated with more improvement at 3 months, regardless of treatment. Baseline QoL had different risks for different magnitudes of clinical change, but overall, the lower the baseline health status, the greater the likelihood of a large improvement in QoL during 3-month follow-up, regardless of CRT. The discrimination (C statistics) of the partial proportional odds model for not worse, at least small improvement, at least moderate improvement, and large improvement were 0.65, 0.68, 0.69, and 0.73, respectively. A sensitivity analysis of the models' performance among subjects with 12-month QoL data available was conducted. At 12 months, the model had better discrimination with C statistics of 0.71, 0.74, 0.76, and 0.79 for not worse, at least small improvement, at least moderate improvement, and large improvement, respectively, and demonstrated excellent calibration (Figures II through V in the Data Supplement). Figure 4 demonstrates a potentially actionable output format for these models when used at the bedside for clinical decision making. In this example, a 72-yearold with a baseline MLHFQ of 52 and QRS duration of 175 ms would have a 54% probability of a large QoL improvement with CRT as compared with 33% without CRT (number needed to treat=5). Conversely a 35-yearold with a baseline MLHFQ of 40 and QRS duration of 130 would have only a 36% probability of a large improvement with CRT versus 31% without CRT (number needed to treat=20). Values are shown as absolute numbers (percentages), mean±SD. ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; MLHFQ, Minnesota Living with Heart Failure Questionnaire; and NYHA, New York Heart Association.
DISCUSSION
Despite the undoubted benefits of CRT, there are concerns that it has been underused in clinical practice, with only about a third of eligible patients being treated. 20, 21 More appropriate use of CRT has been estimated to potentially save >8000 lives per year in the United States alone. 21 A potential reason for the underuse of CRT is the difficulty in weighing the risks and benefits of the procedure for a specific patient. Although a substantial amount of work has been done to try to understand which patients will respond to CRT, benefit has been measured in terms of echocardiographic response or a reduction in morbid or fatal events, despite the fact that patients may care more about the quality of their lives than its quantity. 22 To extend prior reports of the average QoL benefits of CRT in a study population, we developed a method for personalizing the estimated likelihood of QoL improvement with CRT. Such a model could support more evidence-based, patient-centered care by helping patients and their providers understand the benefits that they might expect from CRT, especially when coupled with a model estimating the CRT benefits on survival. 7 Our findings extend prior investigations of the QoL benefits of CRT, which have shown increasing survival with longer QRS duration and in those with more severe heart failure but have not been able to clearly define patient characteristics associated with improved QoL. 4, 7, 23, 24 Our analysis found that after adjusting for QRS duration, QRS morphology does not predict the response to CRT, consistent with 2 prior patient-level analyses 14, 25 but not another. 26 It is notable that the majority of patients (76%) in our analysis had left bundle branch block, and it is possible that those with wide right bundle branch block had some underlying left sided dyssynchrony, so extrapolation to those with pure right bundle branch block may be limited. Also contrary to some previous analyses, 27,28 sex was not predictive of QoL improvement in the final multivariable model, despite women deriving more benefit in unadjusted analyses. We hypothesize that this is because of the worse QoL scores in women at the time of treatment and that once baseline QoL was accounted for sex was no longer independently associated with CRT benefit. Moreover, we found that baseline QoL was very important, where worse baseline health status was associated with a greater likelihood of improvement. Older patients obtained greater benefit in QoL, despite prior studies showing less use of CRT in older patients. 29 Using a coarser assessment of QoL than the MLHFQ questionnaire, the NYHA classification, we found more benefit in those with NYHA III/IV as compared with those with NYHA II.
Clinical Implications
Our data provide an opportunity to estimate the QoL benefits for an individual patient and to use this information, coupled with mortality and periprocedural risks, to engage patients in shared decision making about CRT. 7, 30 Although, our tool only assesses the initial benefits of CRT, it is reassuring that the model continued to perform well at 12 months post-implant. Further work will be needed to define strategies for optimizing CRT to maximize QoL improvement and to define the longer-term QoL benefits of treatment.
Potential Limitations
Our decision to include a patient-reported outcome into the model as opposed to more commonly available NYHA class may hinder implementation. Our rationale to include MLHFQ (or patient-reported outcomes in general) as opposed to NYHA class is that the later is a crude measurement and subject to gaming. There have been several articles explicitly demonstrating low inter-rater reliability of the NYHA with a concordance between 2 different cardiologists' assessments of the same patient of ≈0.54. [31] [32] [33] In contrast, the intraclass correlation of health status questionnaires, such as the KCCQ, are high with an estimate of ≈0.92 in stable patients. 17 Further underscoring the value of collecting patient-reported outcome data is the accuracy of the model when a more detailed, reproducible assessment of health status is used. For these reasons, we think that the improved accuracy of the models is greater and justifies the added burden of collecting patients' health status with a questionnaire.
Our findings should be considered in the context of several potential limitations. QoL change from baseline to 3 months was used as our end point because the largest amount of follow-up QoL data were available at 3 months, and most of the QoL benefit occurred within this Predicted risk estimates are depicted with bars; lines represent 95% confidence intervals. Estimates of mortality taken from Cleland et al. 7 CRT indicates cardiac resynchronization therapy; MLHFQ, Minnesota Living with Heart Failure Questionnaire; OMT, optimal medical therapy; and QoL, quality of life.
timeframe. In sensitivity analysis, the model performed well at 12 months; however, there was not an opportunity to explore longer-term outcomes that may have been associated with greater QoL benefits, which might be particularly relevant in patients with NYHA II. This will require future research with longer-term outcomes, which may be important given the evidence of continuing positive remodeling of the left ventricle ≤18 months after CRT implantation. 34, 35 Second, because there are not welldeveloped thresholds of clinical change for the MLHFQ, we had to model these thresholds based on the clinically important thresholds of change defined by the KCCQ. We used linear regression from patients with simultaneous MLHFQ and KCCQ in REVERSE to estimate clinical meaningful thresholds in MLFHQ because much more work has been conducted to define clinically important thresholds of change in the KCCQ than the MLHFQ. Although we conducted sensitivity analyses and found consistent results, this methodology has not been validated in other datasets, and REVERSE included healthier patients than many CRT trials. Future efforts to better map the MHLFQ to the KCCQ could validate our estimates and might change, presumably modestly, the results of our model by using a different threshold of clinically significant change. Third, we used older CRT studies, which could impact generalizability of our findings to current practice, because our model may underestimate the benefits of CRT with newer, more advanced devices (quadripolar leads, multipoint pacing, adaptive CRT, etc). Although these evolutions in technology may underestimate the benefits of CRT, it is also possible that evolving medical therapies may have improved the health status of patients not treated with CRT. Thus, these models should be considered an initial step in an evolving effort to validate and improve patientspecific outcome estimates. Fourth, the controls groups of the pooled data were not identical, whereas MIRACLE, MIRACLE-ICD, REVERSE, and RAFT had devices implanted but turned off. CARE had only medical therapy. It is thus possible that the greater QoL benefit in CARE may have reflected a placebo effect, further underscoring the value of including all trials in our analyses. Fifth, although independent patient data were available, certain laboratory values and information about peripheral artery disease, lung disease, and ICD shocks (appropriate and inappropriate) were not available to be included in the model. Finally, our model has not been validated in other randomized controlled trials or in registries, and external validation of these models should be pursued.
Conclusions
We identified substantial variability in the benefits of CRT on QoL, which could be modeled using only 3 variables: age, baseline health status, and QRS duration. This model may contribute to the infrastructure for personalizing the benefits of CRT for those being considered for this intervention. Future studies should examine whether the prospective use of this and models that predict procedural risks and long-term morbidity and mortality can improve patients' participation in shared decision making, target the use of CRT to patients most likely to benefit, and whether this approach to precision medicine can enhance the ability of this important technology to improve the outcomes of patients with heart failure.
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